Harvard College

Johns Hopkins University

John Heyman

David A Weitz

John R Gilbert

Andrew B Feldman

Jeffrey S Lin

Andrew S Pekosz

Christiane Wobus

Allon Moshe Klein

Joshua T Wolfe

Huidan Zhang

Kellogg Schwab

Jared D Evans

Joerg G Werner

Timothy Julian

Li Sun

Julie V Brouchon

Brendan Deveney

The present invention generally relates to fluidic droplets and systems and methods for determining immune or other cells. Some aspects of the invention are generally directed to assays that combine sensitive detection of secreted products with detection of target cell death in droplets containing an effector cell, systems and methods to isolate droplets in which one or more cell interactions have occurred, or systems and methods to generate nucleic acid information from cell interactions. In addition, some embodiments of the invention are generally directed to containing two (or more) cells in droplets, e.g., an effector cell and one or more target cells, and determining various interactions between the cells within the droplets, such as whether the effector cell kills the target cell, whether the effector cell releases antibodies, cytokines or other substances that are able to interact with the target cell or are released in the presence of the target cell, or the like.

Microfluidic determination of immune and other cells

The present invention generally relates to polymers and, in particular, to copolymers for stabilizing, e.g., emulsions or droplets. In certain aspects, the copolymers may comprise a relatively hydrophobic monomer and a relatively hydrophilic monomer polymerized together (e.g., randomly) to form the copolymer. Examples of hydrophobic monomers include methacrylates and vinylphenyls; examples of hydrophilic monomers include boronic acids or acid derivatives. Surprisingly, such random copolymers may act as surfactants, e.g., stabilizing droplets within the emulsion. In addition, in some cases, an interfacial film may be produced by exposing the copolymer to a complexing molecule, such as a polyol, that can complex with the copolymer to form the film. In some cases, the film may at least partially surround a droplet, and in certain embodiments, the film may be sufficiently sturdy such that the droplet can be removed from the emulsion. Other aspects include methods of making or using such copolymers (for example, for containing cells in droplets), kits involving such copolymers, or the like.

Copolymers for stabilizing emulsions and/or forming interfacial films, and methods thereof

The present invention generally relates to microfluidics and labeled nucleic acids. In one aspect, the present invention is generally directed to a method, wherein the method includes providing a plurality of droplets comprising particles, the particles comprising oligonucleotides, and attaching a nucleic acid sequence to the oligonucleotides. Certain embodiments are generally directed to systems and methods for splitting a droplet into two or more droplets. Certain embodiments are generally directed to systems and methods for sorting fluidic droplets in a liquid.

Barcoding systems and methods for gene sequencing and other applications

Food products and/or pharmaceutical preparations including (i) viral neutralizing antibodies or antibody fragments anchored to a probiotic microorganism and (ii) a carrier medium for delivering the viral neutralizing antibodies or antibody fragments anchored to probiotic microorganisms to the gut of a mammal. Also provided are methods of making food products and/or pharmaceutical preparations, which can be used to treat existing viral infections or prevent the spread or transmission of viral infection.

Compositions and methods for preventing or relieving symptoms of infections

A method for synthesizing an antiserum for rapid-turnaround therapies includes collecting antibody-secreting cells from a test subject, wherein the test subject has been exposed to a target biological agent and has produced an antibody response; selecting a subset of the antibody-secreting cells, the subset of the antibody-secreting cells producing antibodies that neutralize the target biological agent; generating variable-region-coding DNA sequences from the antibodies that neutralize the target biological agent; tagging amplicons of the variable-region-coding DNA sequences with unique nucleic acid identifiers to associate the variable-region-coding DNA sequences derived from individual ones of the subset of the antibody-secreting cells; analyzing antibody-type distribution in a natural immune response; synthesizing antibodies from the variable-region-coding DNA sequences to form synthetic antibodies; and mixing the synthetic antibodies in a proportion equal to the antibody-type distribution in the natural immune response to form the antiserum.

Synthetic antiserum for rapid-turnaround therapies

Growing community of inventors

Somerville, MA, United States of America

John Heyman